Specifically, we investigated the effects and underlying mechanisms of pharmacological (administration of the immunomodulator FTY720) or genetic (sphingosine kinase-2 deficient (SPHK-2−/−) mice) approaches to alter S1P receptor signaling on the impaired systolic contractility and S1P levels in experimental sepsis. The gene discussed is MBTPS1; the disease is Sepsis.